DDrare: Database of Drug Development for Rare Diseases

Growth hormone (somatropin) (DrugBank: Growth hormone, Somatropin)

2 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	1
78	Hypopituitarism	1

2. Amyotrophic lateral sclerosis [ 508 clinical trials, 530 drugs, (DrugBank: 146 drugs), 170 drug target genes, 221 drug target pathways]

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 508 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00635960 (ClinicalTrials.gov)	March 2007	3/3/2008	Growth Hormone in Amyotrophic Lateral Sclerosis	Efficacy, Safety and Tolerability of Growth Hormone in Patients With Amyotrophic Lateral Sclerosis as add-on Therapy to Riluzole	Amyotrophic Lateral Sclerosis	Drug: Growth Hormone (Somatropin);Drug: Placebo	Federico II University	Istituto Biostrutture e Immagini, CNR Naples;Agenzia Italiana del Farmaco	Completed	40 Years	85 Years	Both	40	Phase 2	Italy

78. Hypopituitarism [ 462 clinical trials, 346 drugs, (DrugBank: 45 drugs), 41 drug target genes, 80 drug target pathways]

Searched query = "Hypopituitarism", "Anterior pituitary hypothyroidism", "Syndrome of abnormal secretion of gonadotropin", "Hyposecretion of gonadotropins", "Adrenocorticotropic hormone deficiency", "ACTH deficiency", "Thyroid-stimulating hormone deficiency", "TSH deficiency", "Growth hormone deficiency", "GH deficiency", "GHD", "CGHD", "AGHD", "Prolactin deficiency", "PRL deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 462 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00271518 (ClinicalTrials.gov)	September 2005	29/12/2005	Treatment of Children With Insufficient Secretion of Growth Hormone	A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of the LB03002 a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Daily Therapy in Treatment Naive Children With Growth Failure Due to Insufficient Secretion of Endogenous Growth Hormone	Growth Hormone Deficiency (GHD)	Drug: growth hormone (somatropin)	LG Life Sciences	BioPartners GmbH	Active, not recruiting	3 Years	11 Years	Both	144	Phase 3	United States